P0963 From trial to practice: No survival benefit from adjuvant mitotane in low-risk adrenocortical carcinoma, insights from a nationwide cohort

European Urology 2026

View at publisher
Authors: C. Silvani, A. Santangelo, A. Stephens, N. Saeedi, J. Considine, T. Zadeh, Bassel R. Salka, M.A. Catanzaro, A. Salonia, Alberto Briganti, Francesco Montorsi, N. Nicolai
+3 more E.M. Montanari, C. Rogers, Firas Abdollah
DOI: 10.1016/s0302-2838(26)01816-6
Cited by: 0

Fields of Study & Subjects

Adrenal and Paraganglionic Tumors Renal cell carcinoma treatment Adrenal Hormones and Disorders

Publication details

Journal / source
European Urology
Volume
89
Pages
S1–S1
Publication date
13 February 2026
Language
EN